Propanc Biopharma retires final convertible note via full conversion to common stock

Propanc Biopharma, Inc.

Retired final convertible promissory note dated June 30, 2022, with 1800 Diagonal Lending LLC.
Full payment made on Feb 15, 2023, converting all outstanding principal and interest into common stock.
Zero balance remaining; no further obligations to issue securities to the holder.
No specific financial impact or conversion terms disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.